WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) today joined more than 100 companies, associations, venture capital firms and universities in sending a letter to key leaders of the U.S. House of Representatives and U.S. Senate to urge a cautious approach to reforming patent law that continues to protect biomedical innovation.
